Advertisement

Selecting Fuchs patients for drug trials involving endothelial cell proliferation

Abstract

Purpose

Fuchs endothelial corneal dystrophy (FECD) might be managed by drug treatment before becoming severe enough to require surgery. For a clinical trial of such a drug, we hypothesize that selecting an adequate number of patients with FECD with only moderately compromised cell densities will be challenging. Thus, the purpose of the present study was to measure the prevalence of patients with FECD exhibiting moderately decreased corneal cell densities.

Methods

A retrospective data mining study (cross-sectional study) was performed on patient charts presenting at a large US northwestern academic health center by searching for diagnosis ICD-9 code 371.57 and Fuchs corneal dystrophies, including those with prior cataract surgeries and/or existing glaucoma. Patients with prior corneal transplants were excluded. Noncontact specular photomicroscopic data (Topcon 2000) were obtained from the central region whenever possible, and individual eyes were grouped according to cell density (cells/mm2): severe (<800), moderate (800-1,500), and mild (>1,500).

Results

The values for 98 eyes from 61 patients with FECD were as follows (mean ± SD): corneal thickness 573 ± 59 μm, cell size 627 ± 336 μm2/cell, coefficient of variation 23 ± 7, and density 1,883 ± 703 cells/mm2. The moderate subgroup with cell density values averaging 1,184 ± 212 (26) comprised 27% of the total FECD patient pool.

Conclusions

Only approximately 1 out of 4 patients with FECD will show moderately compromised corneal cell densities. A moderate level of damage may be optimal for clinical trials for testing topical drugs on endothelial cell viability. Thus, investigators will need to initially screen a fourfold excess of all patients with FECD.

Eur J Ophthalmol 2016; 26(6): 536 - 539

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/ejo.5000761

Authors

Thomas R. Shearer, Winston D. Chamberlain, Atsuko Fujii, Mitsuyoshi Azuma

Article History

Disclosures

Financial support: Funding was provided by Senju Pharmaceutical Co., Ltd.
Conflict of interest: Drs. Shearer and Chamberlain are paid consultants for Senju Pharmaceutical Co., Ltd., a company that may have a commercial interest in the results of this research and technology. Drs. Azuma and Fujii are employees of Senju Pharmaceutical Co., Ltd. These potential conflicts of interest were reviewed, and a management plan approved by the OHSU Conflict of Interest in Research Committee was implemented.
Meeting presentation: Presented in part at the Association for Research in Vision and Ophthalmology annual meeting, Orlando, FL, May 4, 2014.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Integrative Biosciences, Oregon Health & Science University, `Portland, OR - USA
  • Department of Ophthalmology, Oregon Health & Science University, `Portland, OR - USA
  • Laboratory of Ocular Sciences, Senju Pharmaceutical Corporation Ltd., `Portland, OR - USA

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.